Davis Kourtney J, Hinds David, Motsko Stephen P, Goehring Earl, Jones Judith K
Real World Evidence, GlaxoSmithKline R&D, 1250 South Collegeville Rd, Collegeville, PA, 19426-0989, USA.
The Degge Group, Ltd., 9302 Lee Highway, Fairfax, VA, USA.
Drugs Real World Outcomes. 2016 Mar;3(1):53-60. doi: 10.1007/s40801-015-0057-y.
Our objective was to highlight the importance of database selection in observational research and to determine the incidence of corticosteroid-related events in patients exposed to fluticasone propionate intranasal spray (FPNS) compared with other intranasal steroids (INS).
After a feasibility study using an electronic medical record database in the UK (1990-2002), a retrospective cohort study was conducted using a large administrative claims database in the USA from 1994 to 2002 comparing the incidence and rate ratios of steroid-related events among intermittent, sub-chronic, and chronic FPNS use and other INS use episodes.
Most patients used INS intermittently; power was low to evaluate risk associated with chronic use. Significantly elevated adjusted rate ratios were observed in the US study comparing FPNS with other INS for hypercorticism, sinusitis, abscess, and empyema, as well as a significantly decreased rate ratio for cataracts. The US claims database provided greater granularity on covariates and markers of severity to improve control of confounding for this study and time period, but neither database was able to assess the indication for prescription and the UK study could not address the use of INS without a prescription.
The FPNS results were consistent with the risk profile for INS and did not raise any new safety signals at the time of study conduct, which is consistent with the current safety profile. We were not able to discern the extent of potential off-label use of FPNS or other INS. Differences in the available data and healthcare systems highlight important considerations for database selection in the feasibility phase to assess the precision and limitations prior to formal risk evaluation.
我们的目标是强调观察性研究中数据库选择的重要性,并确定与其他鼻用类固醇(INS)相比,使用丙酸氟替卡松鼻喷雾剂(FPNS)的患者中与皮质类固醇相关事件的发生率。
在使用英国电子病历数据库(1990 - 2002年)进行可行性研究后,进行了一项回顾性队列研究,使用美国1994年至2002年的大型行政索赔数据库,比较间歇性、亚慢性和慢性使用FPNS及其他INS期间与类固醇相关事件的发生率和率比。
大多数患者间歇性使用INS;评估慢性使用相关风险的效能较低。在美国的研究中,与其他INS相比,FPNS在皮质醇增多症、鼻窦炎、脓肿和脓胸方面的调整率比显著升高,而白内障的率比显著降低。美国索赔数据库在协变量和严重程度标志物方面提供了更高的粒度,以改善本研究及该时间段内混杂因素的控制,但两个数据库均无法评估处方适应证,且英国的研究无法处理非处方使用INS的情况。
FPNS的结果与INS的风险特征一致,在研究进行时未引发任何新的安全信号,这与当前的安全概况相符。我们无法辨别FPNS或其他INS潜在的超适应证使用程度。可用数据和医疗保健系统的差异凸显了在可行性阶段选择数据库时的重要考虑因素,以便在正式风险评估之前评估其精度和局限性。